

OBSEVA SA CHF0.076923

ISIN: CH1260041939 WKN: 126004193 Asset Class: **Stock**

Company

2024/05/03 17:33:01

Price

0.00

CHF

Difference  -76.92%(0.00)



Contact Details

OBSEVA SA

Tel: +41-22-552-38-40

--

Fax: +

Chemin des Aulx, 12, Plan-les-Ouates

Web: <http://www.obseva.com>

1228 Genf

E-mail: contact@obseva.ch

Company Profile

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2022		2021		2020	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	14,796,000		57,873,000		32,677,000	
Common stock capital		8,100,000		5,912,000		4,043,000
Fixed assets	509,000		23,210,000		25,174,000	
Equity capital of a company		7,848,000		29,465,000		7,384,000
Cash and cash equivalents	13,839,000		49,870,000		27,564,000	
Accrued liabilities		539,000		6,534,000		7,264,000
Other assets	-		-		-	
Current liabilities		6,648,000		21,418,000		19,185,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		809,000		30,200,000		31,282,000
Different income		-		-		-
Other liabilities		270,000		0		812,000
Total assets	15,306,000	15,306,000	81,084,000	81,084,000	57,851,000	57,851,000

Balance notes

	2022	2021	2020
Accounting standard	IFRS	IFRS	IFRS
Employees	15	51	45
Equity ratio	51.28%	36.34%	12.76%
Debt-equity ratio	95.03%	175.18%	683.42%

Others

	2022	2021	2020
Tax Expense Rate	-0.04%	-0.36%	-0.04%

OBSEVA SA CHF0.076923

ISIN: CH1260041939 WKN: 126004193 Asset Class: **Stock**

Income statement

	2022	2021	2020
Turnover	18,754,000	0	0
Net income	-28,536,000	-53,372,000	-77,873,000
EBIT	-20,256,610	-51,680,964	-76,873,180
Operating income before taxes	-28,525,000	-53,178,000	-77,841,000
Cash Flow	-22,105,000	-66,547,000	-68,600,000
Net interest income	-8,813,000	-2,885,000	-3,032,000
Research and development expenses	10,228,000	48,177,000	62,970,000
Income taxes	10,000	193,000	31,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,284,816	0	0

Board of Directors

Luigi Marro	Member of the administrative board
Ernest Loumaye	Chairman of the administrative board

Members of Management Board

Fabien de Ladonchamps	Chairman of Managing Board
-----------------------	----------------------------